Article
Dermatology
Ji-Hye Park, YoungHwan Choi, Hyun Je Kim, Se Jin Oh, Dong-Youn Lee, Jong Hee Lee, Joo-Heung Lee
Summary: This research found that cetuximab-induced acneiform eruption can be effectively controlled with tetracycline-class antibiotics in about 3 months. It may last longer in male and younger patients, and the sooner and more severe it appears, the longer it can last.
Article
Multidisciplinary Sciences
Yuan Yang, Ruizeng Luo, Shengyu Chao, Jiangtao Xue, Dongjie Jiang, Yun Hao Feng, Xin Dong Guo, Dan Luo, Jiaping Zhang, Zhou Li, Zhong Lin Wang
Summary: This article introduces a microneedle-based self-powered transcutaneous electrical stimulation system (mn-STESS), which can improve the pharmacodynamics of epidermal growth factor and overcome the pharmacodynamic challenges associated with its conventional administration strategies.
NATURE COMMUNICATIONS
(2022)
Review
Medicine, General & Internal
Lijuan Zhang, Yanli Song, Nan Jiang, Yaqi Huang, Bo Dong, Wei Li, Yanze He, Yun Chen, Haibin Liu, Rui Yu
Summary: In patients with oesophageal cancer, anti-EGFR treatment significantly improved overall survival, objective response rate, and disease control rate but did not affect progression-free survival. However, anti-EGFR treatment was associated with higher incidences of myelosuppression, diarrhoea, acne-like rash and hypomagnesaemia. Careful monitoring of patients with oesophageal cancer is recommended during anti-EGFR treatment due to these adverse effects.
Editorial Material
Dermatology
Jawaher Tariq A. AlMulhem, Farah A. O. A. Zuaiter
Summary: Acneiform eruption is a severe cutaneous side effect of cetuximab, impacting patients' quality of life and necessitating multidisciplinary collaboration for prevention and treatment. Prevention methods include education, skin care routines, and prophylactic drugs, with oral tetracyclines and systemic corticosteroids being the most effective treatments. Ongoing research is focused on improving the management of cetuximab-induced acneiform eruption.
Article
Dermatology
Rachel Bierbrier, Kathleen D'Aguanno, Sarah Oliel, Yixiao Zeng, Khashayar Esfahani, Kevin Pehr
Summary: Acneiform eruptions are common adverse events of EGFRi therapy, occurring frequently and early. Combination cancer therapy with another chemotherapeutic agent is associated with a lower risk of acneiform eruptions, while other baseline characteristics are not statistically associated. Further research is needed to determine the risk factors for the development of acneiform eruptions.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2023)
Article
Dermatology
Rohit Gupta, Megan F. Craddock
Summary: Selumetinib is a drug used to treat plexiform neurofibromas and low-grade gliomas. However, it can cause acneiform eruptions, which can be effectively treated with isotretinoin. We present a case of a pediatric patient who successfully treated severe acneiform eruption secondary to selumetinib with low-dose isotretinoin.
PEDIATRIC DERMATOLOGY
(2022)
Review
Oncology
Andrew D. J. Pearson, Susan L. Weiner, Peter C. Adamson, Dominik Karres, Gregory Reaman, Raphael Rousseau, Patricia Blanc, Koen Norga, Jeffrey Skolnik, Pam Kearns, Nicole Scobie, Elly Barry, Lynley Marshall, Leona Knox, Hubert Caron, Darshan Wariabharaj, Alberto Pappo, Steven G. DuBois, Lia Gore, Mark Kieran, Brenda Weigel, Elizabeth Fox, Karsten Nysom, Teresa de Rojas, Gilles Vassal
Summary: Rapid evaluation and regulatory approval of new drugs are crucial for improving survival and reducing side-effects for children and adolescents with cancer. ACCELERATE organization facilitates communication and collaboration among academia, industry, patient advocates, and regulators to prioritize drug development and promote a patient-centric approach.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Immunology
Cathal O'Connor, Derek Power, Catherine Gleeson, Cynthia Heffron
Summary: Pembrolizumab, an anti-PD-1 therapy used for treating malignant melanoma, rarely causes folliculitis. A case study reported a 49-year-old male with a history of mild lower limb folliculitis who developed a pustular eruption after 19 doses of pembrolizumab, requiring oral isotretinoin for disease control.
Article
Pharmacology & Pharmacy
Yuran Qiu, Xiaolan Yin, Xinyi Li, Yuanhao Wang, Qiang Fu, Renhua Huang, Shaoyong Lu
Summary: Dual-targeting therapeutics, which combine allosteric and orthosteric drugs, have shown promise in overcoming drug-resistance issues and improving treatment efficacy. Occupancy of the orthosteric sites by therapeutics can enhance allosteric ligand binding and increase the potency of allosteric drugs. Through extensive molecular dynamics simulations and reversed allosteric communication, the molecular mechanism of how osimertinib alters the conformation and reshapes the allosteric site of EGFR mutant has been elucidated, providing insights for future clinical applications of dual-targeting therapeutics.
Article
Medicine, General & Internal
Maren Paulmann, Felix Reinkemeier, Marcus Lehnhardt, Maja Mockenhaupt
Summary: A 42-year-old male patient was initially diagnosed with epidermal necrolysis but later confirmed to have generalized bullous fixed drug eruption. The importance of medical history, clinical presentation, and detailed medication history in accurate diagnosis was highlighted.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
E. Zhou, Feng Wu, Mengfei Guo, Zhengrong Yin, Yumei Li, Minglei Li, Hui Xia, Jingjing Deng, Guanghai Yang, Yang Jin
Summary: The established ERS in this study can predict a poor prognosis for LUAD patients and has the potential to predict drug responses.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Emma-Anne Karlsen, Sam Kahler, Joan Tefay, Shannon R. Joseph, Fiona Simpson
Summary: This review critically analyzes the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.
Article
Oncology
Katsuko Kikuchi, Naoya Yamazaki, Keiko Nozawa, Haruhiko Fukuda, Taro Shibata, Ryunosuke Machida, Tetsuya Hamaguchi, Atsuo Takashima, Hirokazu Shoji, Narikazu Boku, Sumiko Takatsuka, Tatsuya Takenouchi, Tomohiro Nishina, Shusuke Yoshikawa, Masanobu Takahashi, Akiko Hasegawa, Akihito Kawazoe, Toshiki Masuishi, Hitoshi Mizutani, Yoshio Kiyohara
Summary: The study found no significant differences in the severity of facial acneiform eruption (FAfE) and adverse events caused by topical corticosteroids between the two groups over an 8-week period. However, the group starting with a strong corticosteroid showed lower incidence of grade 2 or higher FAfE during the first 2 weeks, suggesting that the regimen ranking up in potency may be more suitable for long-term management of FAfE due to EGFR inhibitor therapy.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Chemistry, Multidisciplinary
Paolo Zucchiatti, Giovanni Birarda, Andrea Cerea, Marta S. Semrau, Aliaksandr Hubarevich, Paola Storici, Francesco De Angelis, Andrea Toma, Lisa Vaccari
Summary: This study demonstrates the potential of SEIRA microscopy in detecting subtle secondary structure modifications associated with the binding of Lapatinib to EGFR. By optimizing techniques and data analysis, the researchers successfully identified secondary structure modifications in EGFR related to a few amino acids.
Article
Oncology
Sojung Park, Sung Yong Lee, Dojin Kim, Yun Su Sim, Jeong-Seon Ryu, Juwhan Choi, Su Hwan Lee, Yon Ju Ryu, Jin Hwa Lee, Jung Hyun Chang
Summary: This study investigated 363 patients with advanced lung adenocarcinoma harboring EGFR mutations and evaluated the efficacy of afatinib, erlotinib, and gefitinib according to mutation type. E19del and L858R mutations were associated with superior progression-free survival and overall survival compared to uncommon mutations. Afatinib showed significantly longer progression-free survival across all EGFR mutation types.